{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:35:53Z","timestamp":1791005753913,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2503503"],"award-info":[{"award-number":["2022YFC2503503"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2503504"],"award-info":[{"award-number":["2022YFC2503504"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejphar.2025.177546","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T23:05:34Z","timestamp":1742943934000},"page":"177546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Effect of CYP2C19 genotype on outcomes of treatment with ticagrelor versus clopidogrel in acute coronary syndrome patients with diabetes mellitus: A analysis in a large-scale, real-world study"],"prefix":"10.1016","volume":"996","author":[{"given":"Haofu","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaohan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3679-8248","authenticated-orcid":false,"given":"Kun","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhao","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-6737","authenticated-orcid":false,"given":"Yaling","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177546_bib1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jcin.2020.01.226","article-title":"Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score","volume":"13","author":"Angiolillo","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ejphar.2025.177546_bib2","first-page":"160","article-title":"Canadian cardiovascular society\/Canadian association of interventional cardiology 2023 focused update of the guidelines for the use of antiplatelet therapy","volume":"40","author":"Bainey","year":"2024","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ejphar.2025.177546_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008125","article-title":"Ticagrelor use in acute myocardial infarction: insights from the national cardiovascular data registry","volume":"7","author":"Basra","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejphar.2025.177546_bib4","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2025.177546_bib5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1160\/TH15-12-0981","article-title":"Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial","volume":"116","author":"Carreras","year":"2016","journal-title":"Thromb. Haemost"},{"key":"10.1016\/j.ejphar.2025.177546_bib6","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jacasi.2022.07.005","article-title":"Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome and diabetes mellitus","volume":"2","author":"Choi","year":"2022","journal-title":"JACC Asia"},{"key":"10.1016\/j.ejphar.2025.177546_bib7","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","article-title":"A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI","volume":"381","author":"Claassens","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.177546_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094967","article-title":"Chronic inflammatory status observed in patients with type 2 diabetes induces modulation of cytochrome P450 expression and activity","volume":"22","author":"Darakjian","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2025.177546_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ahj.2020.07.014","article-title":"Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus","volume":"229","author":"Elharram","year":"2020","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ejphar.2025.177546_bib10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/ehjcvp\/pvae036","article-title":"Comparative effects of different antiplatelet strategies in carriers of CYP2C19 loss-of-function alleles: a network meta-analysis","volume":"10","author":"Galli","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ejphar.2025.177546_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e22214","article-title":"Advances and Perspectives in methods for identifying high platelet reactivity","volume":"9","author":"Gao","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.ejphar.2025.177546_bib12","first-page":"239","article-title":"Clinical utility of CYP2C19 genotype-guided antiplatelet therapy in patients at risk of adverse cardiovascular and cerebrovascular events: a review of emerging evidence","volume":"13","author":"Gower","year":"2020","journal-title":"Pharmgenomics Pers Med"},{"key":"10.1016\/j.ejphar.2025.177546_bib13","article-title":"Derivation and validation of the PRECISE-HBR score to predict bleeding after percutaneous coronary intervention","author":"Gragnano","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.177546_bib14","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/eurheartj\/ehac101","article-title":"Adherence to P2Y12 inhibitors in acute coronary syndrome after a percutaneous coronary intervention: what can we improve?","volume":"43","author":"Han","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2025.177546_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5546260","article-title":"Clinical outcome between ticagrelor versus clopidogrel in patients with acute coronary syndrome and diabetes","author":"He","year":"2021","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.ejphar.2025.177546_bib16","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1001\/jama.2011.1880","article-title":"CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis","volume":"306","author":"Holmes","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2025.177546_bib17","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejphar.2025.177546_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11239-011-0611-8","article-title":"Genetic determinants of platelet response to clopidogrel","volume":"32","author":"Kubica","year":"2011","journal-title":"J. Thromb. Thrombolysis"},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2025.177546_bib19","first-page":"1032","article-title":"Comparison of the efficacy and safety of ticagrelor and clopidogrel in patients with acute coronary syndrome after risk stratification","volume":"97","author":"Li","year":"2021","journal-title":"Cathet. Cardiovasc. Interv."},{"key":"10.1016\/j.ejphar.2025.177546_bib20","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s40265-024-02076-7","article-title":"Impact of CYP2C19 genotype status on clinical outcomes in patients with symptomatic coronary artery disease, stroke, and peripheral arterial disease: a systematic review and meta-analysis","volume":"84","author":"Maas","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2025.177546_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.991646","article-title":"Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy","volume":"9","author":"Nguyen","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.ejphar.2025.177546_bib22","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1161\/CIR.0000000000001257","article-title":"CYP2C19 genetic testing for oral P2Y12 inhibitor therapy: a scientific statement from the American heart association","volume":"150","author":"Pereira","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2025.177546_bib23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.2020.12443","article-title":"Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial","volume":"324","author":"Pereira","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2025.177546_bib24","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.mayocp.2023.02.004","article-title":"Contemporary use of ticagrelor vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GRACE risk score stratification-based analysis in a large-scale, real-world study from China","volume":"98","author":"Qiu","year":"2023","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ejphar.2025.177546_bib25","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","article-title":"Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial","volume":"379","author":"Roberts","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177546_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ehjcvp\/pvv034","article-title":"Contemporary use of ticagrelor in patients with acute coronary syndrome: insights from Swedish web system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART)","volume":"2","author":"Sahlen","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.ejphar.2025.177546_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177872","article-title":"The clinical efficacy and safety evaluation of ticagrelor for acute coronary syndrome in general ACS patients and diabetic patients: a systematic review and meta-analysis","volume":"12","author":"Tan","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.177546_bib28","doi-asserted-by":"crossref","DOI":"10.33963\/v.phj.101890","article-title":"Can CYP2C19 genotyping improve antiplatelet therapy efficacy in real-life practice? Recent advances","author":"Tantry","year":"2024","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.ejphar.2025.177546_bib29","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.jacc.2024.02.015","article-title":"Effectiveness of clopidogrel vs alternative P2Y(12) inhibitors based on the ABCD-GENE score","volume":"83","author":"Thomas","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2025.177546_bib30","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/cpt.1911","article-title":"Genomewide association study of platelet reactivity and cardiovascular response in patients treated with clopidogrel: a study by the international clopidogrel pharmacogenomics Consortium","volume":"108","author":"Verma","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2025.177546_bib31","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.jcin.2013.06.010","article-title":"Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease","volume":"6","author":"Viviani Anselmi","year":"2013","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ejphar.2025.177546_bib32","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925003000?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925003000?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:30:09Z","timestamp":1762144209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925003000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":32,"alternative-id":["S0014299925003000"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177546","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of CYP2C19 genotype on outcomes of treatment with ticagrelor versus clopidogrel in acute coronary syndrome patients with diabetes mellitus: A analysis in a large-scale, real-world study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177546"}}